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Developments in radiotherapy during the past 10–
15 years, which have been driven largely by techno-
logical advances, have been nothing short of
remarkable. Significant advances in tumour imaging,
in radiotherapy treatment planning, and in dose de-
livery techniques have all contributed to improved
treatment outcomes and have, in some situations, led
to important changes in overall therapeutic approach.
IMPROVED TARGET VOLUME DEFINITION
The advent of computed tomography (CT) simula-
tion in the early 1990s was pivotal: for the first time,
anatomic information could be incorporated directly
into the radiotherapy treatment plan, providing much
more precise identification of the boundaries of the
tumour and of surrounding structures. Definitions
developed by the International Commission on Ra-
diation Units and Measurements 1,2 led to standard-
ization of nomenclature with respect to the target
volume and organs at risk, and spawned investiga-
tions to determine minimum margins that ensure ad-
equate coverage of the tumour. In many situations,
the resulting target volumes are now much different
from those that would previously have constituted
standard practice.
Incorporation of anatomic information acquired
from magnetic resonance imaging (MRI) has been
immensely helpful for tumours that are better visual-
ized using that modality—for example, central ner-
vous system tumours, and soft tissue and bone
sarcomas. Now in the era of functional imaging,
positron emission tomography and magnetic reso-
nance spectroscopy can not only add information criti-
cal for target volume definition, but can also identify
areas within a tumour that may be less responsive to
treatment and could be targeted to receive a higher
radiation dose 3. The foregoing modalities, as well as
functional MRI, can also be used to identify structures
that should be avoided so as to reduce the risks asso-
ciated with treatment—as, for example, in patients
with tumours in the central nervous system.
BETTER TREATMENT PLANNING AND
RADIATION DOSE DELIVERY
Concurrent with developments in target volume defi-
nition, tremendous progress has been made in treat-
ment planning and radiation dose delivery techniques.
For external-beam radiotherapy, conformality of dose
delivery to the target volume is much more easily
achieved now than in the past—using, for example,
three-dimensional (3D) inverse treatment planning
techniques combined with intensity-modulated dose
delivery. Online treatment verification by ultrasonog-
raphy or CT permits smaller safety margins to be used,
which further reduces the risk of damage to normal
tissues surrounding the target volume.
Improved immobilization techniques have been
particularly critical in some situations: for example,
stereotactic frames for patients with central nervous
system tumours, or respiratory gating procedures for
treatment of lung and hepatic tumours. Greater pre-
cision in dose delivery has in turn permitted safe use
of dose escalation in some situations or, alternatively,
much shortened fractionation schedules, such as a
20-Gy, 3-fraction schedule for patients with cancer
of the lung being treated with curative intent, who in
the past would have received a similar total dose, but
delivered in 30 daily fractions over 6 weeks.
Important developments have also occurred in
brachytherapy. Generally viewed as the ultimate con-
formal treatment, brachytherapy has similarly ben-
efited from incorporation of 3D imaging into the
treatment planning and dose delivery processes and
from improved delivery methods. As a result,
brachytherapy is now used in a larger proportion of
patients than in the past, either in combination with
external-beam radiotherapy or sometimes as the sole
treatment (such as in patients with cancer of the rec-FREEMAN and PODGORSAK
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tum), replacing protracted courses of combined che-
motherapy and radiotherapy.
New treatment delivery devices are coming onto
the market every year, supporting and encouraging
these changes in practice. Recent examples for ex-
ternal-beam radiotherapy include miniaturized,
robotically-guided linear accelerators that adjust to
the position of the tumour each day. In brachytherapy,
the development of new applicators has expanded the
indications for brachytherapy. Protons—whose physi-
cal properties make them extremely interesting for
use in radiotherapy—are becoming more widely
available.
All of these improvements have come at a cost in
terms of both the equipment itself and the additional
time and expertise required to use the equipment op-
timally. However, these additional expenses need to
be evaluated in the context of savings to society
achieved by improving tumour control and overall
survival, or by reducing the side effects of treatment,
or both. Moreover, in the context of overall expendi-
ture for cancer care in developed countries, radio-
therapy is inexpensive as compared with other
treatments that have become standard over recent
years—for example, hormonal treatment for men with
prostate cancer and trastuzumab for women with
breast cancer. The overall expenditure for radio-
therapy, used in more than 50% of all patients, repre-
sents a rather small fraction of the total expenditure
for cancer care. Even the newer radiation modalities
such as protons or heavy ions, although requiring
seemingly enormous capital outlays for infrastruc-
ture and equipment, have been estimated to be cost-
effective when evaluated in these terms.
EDUCATION, TRAINING, AND TEAMWORK
A favourable treatment outcome depends more than
ever on the availability of a highly skilled team con-
sisting of radiation oncologists, medical physicists,
and radiation therapists (technologists), and on care-
ful attention to every aspect of the treatment plan-
ning and dose delivery process. Education and
training of each of these professionals is now very
demanding, requiring knowledge not only of medi-
cine but also, increasingly, sound knowledge of medi-
cal physics, technology, theory of imaging and dose
delivery, and computer science. Further progress will
be critically dependent on the knowledge and skills
of each professional group, on how well they work
together as a team, and on their collaborations with
molecular biologists and industry.
THE FUTURE
Developments in molecular biology, imaging tech-
nology, and newer delivery techniques continue
apace. Already, advanced dosimetry techniques such
as Monte Carlo simulation are allowing for improved
integration of anatomic information into treatment
planning and delivery of “personalized” treatment that
is not only adapted to the clinical situation at the start
of therapy, but that is also modulated if necessary
during the course of treatment in response to changes
in the position, size, or shape of the tumour. In the
not-too-distant future, advanced imaging technolo-
gies will allow for molecular changes that take place
in the tumour and surrounding normal tissues to be
monitored during a course of treatment and for treat-
ment to be modulated as appropriate to achieve maxi-
mum therapeutic effect.
These are indeed exciting times in radiation on-
cology, and further significant gains of major clini-
cal relevance for patients can reasonably be
anticipated over the coming years.
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